HETERODIMERS OF GLUTAMIC ACID
4 Assignments
0 Petitions
Accused Products
Abstract
Compounds of Formula (Ia)
wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR′R′,
Q is C(O), O, NR′, S, S(O)2, C(O)2 (CH2)p
Y is C(O), O, NR′, S, S(O)2, C(O)2 (CH2)p
Z is H or C1-C4 alkyl,
R′ is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.
6 Citations
57 Claims
- 1. A compound of Formula (I)
-
18. A glutamate-urea-lysine PSMA-binding whose IC50 inhibition of PSMA is less than 20 nM, wherein the glutamate-urea-lysine PSMA-binding moiety is a glutamate-urea-α
- or β
-amino acid heterodimer coupled through the α
-NH2 or β
-NH2 groups. - View Dependent Claims (19)
- or β
-
20-44. -44. (canceled)
- 55. A compound of formula III:
-
57-67. -67. (canceled)
Specification